XARELTO® Helps Protect Against Blood Clot-Related Events

XARELTO® is approved by the FDA to help reduce the risk of blood clots in common conditions like atrial fibrillation (AFib), deep vein thrombosis (DVT), and pulmonary embolism (PE). It is also approved to reduce the risk of major cardiovascular events in conditions for which no other anticoagulant has been approved before, such as coronary artery disease (CAD) and peripheral artery disease (PAD). More than 40 million people worldwide have been prescribed XARELTO®.

Get Started by Choosing Your Condition Below:

*Major cardiovascular events = heart attack, stroke, cardiovascular death.